Department of Urology, Mayo Clinic, Rochester, MN 55905, USA.
Urology. 2010 Sep;76(3):580-6. doi: 10.1016/j.urology.2009.12.037. Epub 2010 Mar 12.
To evaluate the impact of the category of unclassified renal cell carcinoma (URCC) on survival following nephrectomy.
Patients with clear cell RCC (ccRCC, n = 3048) and URCC (n = 38) were identified. Patients with URCC were matched 4:1 with ccRCC patients based on year of surgery, symptoms at presentation, tumor size, stage, regional lymph node involvement, metastases, grade, coagulative tumor necrosis, and sarcomatoid differentiation. Survival was estimated using the Kaplan-Meier method and compared between ccRCC and URCC patients using log-rank tests.
Patients with URCC were more likely to have regional lymph node involvement (P <.001), higher grade (P <.001), tumor necrosis (P <.001), and sarcomatoid differentiation (P <.001) as compared to patients with ccRCC. Overall survival was not significantly different between URCC and ccRCC patients in either the unmatched (P = .337) or matched (P = .345) cohorts. Cancer-specific survival was significantly worse for URCC patients compared with unmatched ccRCC patients (P = .020). However, this difference was not statistically significant when the URCC patients were compared with the matched cohort (P = .688). Distant metastases-free survival was somewhat worse for M0 URCC patients compared with unmatched M0 ccRCC patients (P = .063), but not in the matched cohort (P = .788).
Although URCC is more likely to present with advanced clinicopathologic features compared with ccRCC, no statistically significant differences in outcome were noted after adjusting for these features in a matched analysis.
评估未分类肾细胞癌(URCC)类别对肾切除术后生存的影响。
确定了透明细胞肾细胞癌(ccRCC,n = 3048)和 URCC(n = 38)患者。URCC 患者根据手术年份、就诊时的症状、肿瘤大小、分期、区域淋巴结受累、转移、分级、凝血性肿瘤坏死和肉瘤样分化,与 ccRCC 患者进行 4:1 匹配。使用 Kaplan-Meier 方法估计生存情况,并使用对数秩检验比较 ccRCC 和 URCC 患者之间的生存情况。
与 ccRCC 患者相比,URCC 患者更有可能出现区域淋巴结受累(P <.001)、更高的分级(P <.001)、肿瘤坏死(P <.001)和肉瘤样分化(P <.001)。在未匹配(P =.337)或匹配(P =.345)队列中,URCC 和 ccRCC 患者的总生存均无显著差异。URCC 患者的癌症特异性生存明显差于未匹配的 ccRCC 患者(P =.020)。然而,当将 URCC 患者与匹配队列进行比较时,这种差异没有统计学意义(P =.688)。与未匹配的 M0 ccRCC 患者相比,M0 URCC 患者的远处无转移生存稍差(P =.063),但在匹配队列中则没有(P =.788)。
尽管与 ccRCC 相比,URCC 更有可能表现出晚期临床病理特征,但在匹配分析中调整这些特征后,在结局方面没有观察到统计学上的显著差异。